TNFSF13B Antibody - Premium Quality for Your Research Needs

Discover the high-quality TNFSF13B antibody from Alpha Lifetech Incorporation, designed for researchers seeking reliable tools for their studies. This antibody specifically targets TNFSF13B, also known as BLyS (B Lymphocyte Stimulator), a crucial Protein involved in B cell survival and maturation. Its role in autoimmune diseases and immune regulation makes it an essential focus for research in immunology, Crafted through rigorous validation processes, this antibody ensures specificity and sensitivity, making it suitable for various applications, including Western blotting, ELISA, and immunohistochemistry. Researchers can rely on Alpha Lifetech’s commitment to quality, as every batch undergoes meticulous testing to deliver consistent performance, With easy-to-use formats and supporting documentation, this TNFSF13B antibody stands as a valuable asset in advancing your research on B cell biology and autoimmune disorders. Trust Alpha Lifetech Incorporation for exceptional products that empower scientific discovery and innovation

Hot Selling Product

ADT1566-RSV-neutralizing Human Antibody (Am14) Biosimilar-(RSV)-Research Biosimilar Antibody

ADT1043-Anti-CD28 Biosimilar Antibody– Anti-CD28(Tp44) mAb – Research Grade

ADT1006-Abelacimab Biosimilar (F11)-Research Biosimilar Antibody

ADT1744-Human Anti-VEGFAxANGPT2 Bispecific Antibody

ADT1749-Human Anti-CD3ExCD20 Bispecific Antibody

ADT1750-Human Anti-CD3xBCMA Bispecific Antibody

Don't Miss These TNFSF13B antibody Ahead of the Curve Industry Giant

In the rapidly evolving landscape of biopharmaceuticals, staying ahead of the curve is essential, especially when sourcing high-quality reagents. Alpha Lifetech Inc., a pioneer in membrane protein production and monoclonal development, offers an extensive portfolio that includes nearly 10,000 premium products, among which the TNFSF13B antibody stands out as a game-changer for researchers and developers focused on therapeutic advancements. The TNFSF13B antibody is vital for numerous applications in immunology and cancer research, providing unparalleled specificity and sensitivity. With a robust foundation built by seasoned scientists, Alpha Lifetech Inc. ensures that each product is developed with precision, meeting the stringent demands of today's market. By choosing our reagents, global procurement specialists can access cutting-edge tools that facilitate groundbreaking discoveries and drive innovative solutions. As the industry continues to face the challenges of drug development and therapeutic intervention, securing high-quality reagents like the TNFSF13B antibody is pivotal. Partner with Alpha Lifetech Inc. to enhance your research capabilities and maintain a competitive edge in the biopharmaceutical sector. Don’t miss the opportunity to explore our extensive offerings that are designed to empower your scientific endeavors.

Don't Miss These TNFSF13B Antibody Ahead of the Curve Industry Giant

Antibody Name	Supplier	Application	Validation Type	Price (USD)	Availability
TNFSF13B Monoclonal Antibody	Supplier A	WB, IHC	Post-translational Modification	150	In Stock
TNFSF13B Recombinant Antibody	Supplier B	ELISA, Flow Cytometry	Full Length	200	Pre-order
TNFSF13B Polyclonal Antibody	Supplier C	IHC, IF	Cross-reactive	125	In Stock
TNFSF13B Neutralizing Antibody	Supplier D	Functional Assays	Blocking	175	Limited Stock

Analysis of TNFSF13B Antibody Market Growth Trends

The TNFSF13B antibody market has shown robust growth from 2018 to 2023, as indicated by the bar chart demonstrating annual market values in million USD. The market commenced at a modest value of 10 million USD in 2018, marking the establishment of research and development initiatives in this segment. By 2019, a slight increase to 15 million USD reflected growing interest from various pharmaceutical entities. The real acceleration occurred in 2020 with market growth reaching 25 million USD, corresponding with a surge in clinical trials and preclinical investigations. The subsequent years illustrated a phenomenal increase, culminating in a projected value of 90 million USD by 2023. This rapid growth can be attributed to heightened demand for therapeutic applications in autoimmune disorders and cancers, along with significant investments in biotechnology. The trend highlights the potential of TNFSF13B antibodies in advancing treatment efficacy, thus positioning stakeholders to capitalize on emerging opportunities in this evolving market landscape. The consistent upward trajectory underscores the importance of innovation and research in meeting the needs of healthcare providers and patients alike.